Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03860623
Other study ID # A16042015
Secondary ID
Status Completed
Phase
First received
Last updated
Start date November 7, 2018
Est. completion date October 28, 2022

Study information

Verified date October 2022
Source University of Nottingham
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Obesity is a complicated condition that is poorly understood. The aim of this study is to increase our knowledge of how the condition may arise, and what makes obese people remain obese. We will be investigating 12 people who are overweight and comparing them to 12 people who are lean, to look at how quickly food empties out of the stomach (gastric emptying) and travels through the gut, what the blood flow to the gut is, and also to examine the hormones which are involved in determining how full people feel after eating. In order to do this, we will be using a magnetic resonance imaging (MRI) scanner, and performing blood tests. The rate of gastric emptying may have an impact on satiety (how full one feels) and has been implied in the development of obesity. This effect has been shown to impact on subsequent meal intake to a greater degree in overweight subjects, and may be due to a difference in gastric emptying of food in overweight individuals, or to hormones such as ghrelin, glucagon-like peptide 1, and Peptide YY.


Description:

The World Health Organisation (WHO) has deemed being overweight or obese as the fifth leading cause for global deaths, with more than 1.9 billion adults being defined as overweight, and 600 million defined as being obese. Conditions associated with obesity, such as stroke, type 2 diabetes, certain cancers, cardiovascular, fatty liver and airway disease can lead to premature death. Obesity results from an imbalance in energy intake versus expenditure, and fat mass accumulates. Studies have indicated that obese animals have a faster gastric emptying time, a weaker contraction of the duodenum, but a stronger contraction and relaxation of the ileum, with associated changes in gastrointestinal neurohormonal levels. The rate of gastric emptying may have an impact on feelings of satiety and has been implied in the pathogenesis of obesity. Moreover, mesenteric blood flow increases 3-fold following a meal and in a swine experimental model, a reduction in weight gain was seen when blood flow was intentionally limited to the gut using flow-restricting endovascular stenting. The authors concluded that this intervention may play a role in the treatment of obesity where other interventions have failed or are inappropriate; however the role of blood flow to the gut in obese individuals is important to elucidate. We hypothesize that nutrient absorption in obese and healthy weight individuals after a standardized meal is determined by differences in gastric emptying and mesenteric blood flow which give rise to different insulin, glucose and gut hormone responses. These may be contributory mechanisms to the evolution or maintenance of obesity. The aim of this study is to establish the effects of food ingestion on gastric emptying, gallbladder emptying, small bowel water content and splanchnic blood flow as measured by serial magnetic resonance imaging (MRI) in the context of changes in plasma gastrointestinal hormone secretion in human subjects who are obese or healthy weight. In addition, this pilot study will provide the data necessary to power a larger study investigating methods of dietary manipulation in the treatment of obesity. Method: In order to normalize the pre-study diet, volunteers will have consumed a standard diet for the 3 days immediately before the study visit, which will be based on foods in their normal diet and will be designed to meet their estimated energy requirements and provide 15% of total daily energy intake as protein, 35% as fat and 50% as carbohydrate. Participants will report at 0800 hours following a fast from midnight and after having abstained from alcohol, nicotine, and caffeine from 1800 hours the day before. On arrival, participants will be given a drink of water (200ml). A retrograde cannula will be inserted into a dorsal foot vein after prior intradermal infiltration of 1% lidocaine, with the foot placed in a magnetic resonance (MR) compatible warming box that we have developed, for arterialized-venous blood sampling. Prior to baseline blood sampling, participants will undergo a magnetic resonance imaging (MRI) scan to determine baseline values for superior mesenteric artery (SMA) blood flow, small bowel water content and gastric fluid and gas volumes. Liver fat, visceral fat and subcutaneous fat volumes will also be assessed at this time. Subsequently, a blood sample will be drawn for analysis of concentrations of hemoglobin, glucose, insulin, glucagon-like peptide 1 (GLP-1), glucagon-like peptide 2 (GLP-2), ghrelin and peptide YY (PYY). Serum osmolality will also be measured and subjective appetite assessed using visual analogue scales. The participants will then be given the test meal (in an upright, seated position) and asked to consume it within 15 minutes. The test meal will be comprised of pasta, cheese and tomato sauce, and provides 13% of total energy (E) from protein, 39%E fat, and 48%E carbohydrate. Following the test meal (time = 0 minutes), subjective appetite will be measured as before, then participants will be scanned at 30 minute intervals for 4 hours to assess gastric emptying, gastric accommodation, gastric motility and small bowel water content, as well as SMA blood flow. Blood samples will be drawn at 15 minutes, then every half hour until 240 minutes after the test meal, with a final blood sample taken at 300 minutes. Subjective appetite will be assessed every hour over the 300 minute study.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date October 28, 2022
Est. primary completion date December 31, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: - BMI 30-40 kg/m2 - BMI 18-25 kg/m2; those with BMI up to 28kg/m2 will be included if waist circumference is <96cm. - Males - Aged 18-60yrs Exclusion Criteria: - Acute illness in the preceding 6 weeks - Taking regular medication - History of deep vein thrombosis or clotting disorders - Hypertension - Diabetes - Any clinically significant findings at screening - History of substance abuse - Demonstrating factors precluding safe MRI - History of gastrointestinal motility disorders (e.g. gastroesophageal reflux disease -irritable bowel syndrome, gastroparesis, sphincter of Oddi dysfunction, etc.) - Previous thoracic or abdominal surgery. - Those who report having =3 bowel movements/week or >2/day.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United Kingdom Queens Medical Centre Nottingham Notts

Sponsors (1)

Lead Sponsor Collaborator
University of Nottingham

Country where clinical trial is conducted

United Kingdom, 

References & Publications (5)

Alyami J, Spiller RC, Marciani L. Magnetic resonance imaging to evaluate gastrointestinal function. Neurogastroenterol Motil. 2015 Dec;27(12):1687-92. doi: 10.1111/nmo.12726. Review. — View Citation

Fu XY, Li Z, Zhang N, Yu HT, Wang SR, Liu JR. Effects of gastrointestinal motility on obesity. Nutr Metab (Lond). 2014 Jan 7;11(1):3. doi: 10.1186/1743-7075-11-3. — View Citation

Hoad CL, Parker H, Hudders N, Costigan C, Cox EF, Perkins AC, Blackshaw PE, Marciani L, Spiller RC, Fox MR, Gowland PA. Measurement of gastric meal and secretion volumes using magnetic resonance imaging. Phys Med Biol. 2015 Feb 7;60(3):1367-83. doi: 10.1088/0031-9155/60/3/1367. Epub 2015 Jan 16. — View Citation

Totman JJ, Marciani L, Foley S, Campbell E, Hoad CL, Macdonald IA, Spiller RC, Gowland PA. Characterization of the time course of the superior mesenteric, abdominal aorta, internal carotid and vertebral arteries blood flow response to the oral glucose challenge test using magnetic resonance imaging. Physiol Meas. 2009 Oct;30(10):1117-36. doi: 10.1088/0967-3334/30/10/011. Epub 2009 Sep 16. — View Citation

Vatner SF, Franklin D, Van Citters RL. Mesenteric vasoactivity associated with eating and digestion in the conscious dog. Am J Physiol. 1970 Jul;219(1):170-4. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Gastric emptying rate time taken for a standard meal to empty from the stomach, assessed by serial volume measurements of the stomach using magnetic resonance imaging 240 minutes after feeding
Secondary Stomach volume in the fasted state volume of the stomach measured by magnetic resonance imaging baseline
Secondary Superior mesenteric artery (SMA) blood flow in the fasted state blood flow in the SMA assessed using magnetic resonance imaging baseline
Secondary superior mesenteric artery (SMA) blood flow response to feeding blood flow response to feeding, determined in the SMA every half hour using magnetic resonance imaging 240 minutes after feeding
Secondary Fasting blood glucose concentration whole blood glucose concentration assessed using a Hemocue glucose analyser before feeding
Secondary Blood glucose response to feeding whole blood glucose concentration response to feeding, assessed by serial sampling using a Hemocue glucose analyser 300 minutes after feeding
Secondary Fasting insulin concentration serum insulin concentration in the fasted state measured at a later date using a radio-immunoassay (RIA) baseline
Secondary serum insulin response to feeding serum insulin concentration response to feeding, assessed by serial sampling and measured at a later date using a RIA 300 minutes after feeding
Secondary Fasting plasma GLP-1 concentration Plasma GLP-1 concentration in the fasted state, measured at a later date using an enzyme-linked immunosorbent assay (ELISA) baseline
Secondary Plasma GLP-1 response to feeding Plasma GLP-1 concentration response to feeding, assessed by serial sampling and measured at a later date using an ELISA 300 minutes after feeding
Secondary Fasting plasma GLP-2 concentration Plasma GLP-2 concentration in the fasted state, measured at a later date using an enzyme-linked immunosorbent assay (ELISA) baseline
Secondary Plasma GLP-2 response to feeding Plasma GLP-2 concentration response to feeding, assessed by serial sampling and measured at a later date using an ELISA 300 minutes after feeding
Secondary Fasting plasma Ghrelin Plasma Ghrelin concentration in the fasted state measured at a later date using a RIA baseline
Secondary Plasma Ghrelin response to feeding Plasma Ghrelin concentration response to feeding assessed by serial sampling and measured at a later date using a RIA 300 minutes after feeding
Secondary Fasting plasma peptide YY (PYY) Plasma PYY concentration in the fasted state measured at a later date using a RIA baseline
Secondary Plasma peptide YY (PYY) response to feeding Plasma PYY concentration response to feeding assessed by serial sampling and measured at a later date using a RIA 300 minutes after feeding
Secondary Subjective satiety in the fasted state Satiety of individuals in the fasted state will be assessed using 4 visual analogue scales ('How hungry do you feel', 'how much food do you think that you could eat', how strong is your desire to eat' and how full do you feel') baseline
Secondary Subjective satiety after eating Satiety immediately after eating the standard meal will be assessed using 4 visual analogue scales ('How hungry do you feel', 'how much food do you think that you could eat', how strong is your desire to eat' and 'how full do you feel') immediately after eating the standard meal
Secondary Subjective satiety response to eating The satiety response to the standard meal will be assessed over the 300 minute study period using hourly collection of 4 visual analogue scales ('How hungry do you feel', 'how much food do you think that you could eat', how strong is your desire to eat' and 'how full do you feel') 300 minutes after eating
Secondary visceral adiposity amount of visceral fat present, determined by MRI of the torso baseline
Secondary subcutaneous adiposity thickness of the subcutaneous fat layer on the torso, determined by MRI before feeding
Secondary hepatic lipid content liver triacylglyceride content will be estimated using proton magnetic resonance spectroscopy baseline
Secondary Attrition rate Number of participants completing the protocol as a proportion of those who were recruited to the study 1 year
Secondary Recruitment rate number of people volunteering to take part in the study as a proportion of those expressing initial interest 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2